ATE260653T1 - Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen - Google Patents
Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungenInfo
- Publication number
- ATE260653T1 ATE260653T1 AT00943374T AT00943374T ATE260653T1 AT E260653 T1 ATE260653 T1 AT E260653T1 AT 00943374 T AT00943374 T AT 00943374T AT 00943374 T AT00943374 T AT 00943374T AT E260653 T1 ATE260653 T1 AT E260653T1
- Authority
- AT
- Austria
- Prior art keywords
- naaladase inhibitors
- memory disorders
- treat anxiety
- anxiety
- disorders
- Prior art date
Links
- 208000019901 Anxiety disease Diseases 0.000 title abstract 3
- 230000036506 anxiety Effects 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000026139 Memory disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 abstract 1
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 abstract 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 229930195712 glutamate Natural products 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 206010027175 memory impairment Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/345,782 US6228888B1 (en) | 1999-07-01 | 1999-07-01 | Methods for treating anxiety, anxiety disorders and memory impairment using naaladase inhibitors |
| PCT/US2000/018260 WO2001001974A2 (en) | 1999-07-01 | 2000-06-30 | Naaladase inhibitors in anxiety and memory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE260653T1 true ATE260653T1 (de) | 2004-03-15 |
Family
ID=23356457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00943374T ATE260653T1 (de) | 1999-07-01 | 2000-06-30 | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US6228888B1 (de) |
| EP (1) | EP1202717B1 (de) |
| JP (1) | JP2003503451A (de) |
| AT (1) | ATE260653T1 (de) |
| AU (2) | AU5785100A (de) |
| CA (1) | CA2378467A1 (de) |
| DE (1) | DE60008753D1 (de) |
| MX (1) | MXPA02000255A (de) |
| WO (1) | WO2001001974A2 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
| MXPA01000144A (es) * | 1998-07-06 | 2002-10-17 | Guilford Pharm Inc | Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos. |
| US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6528499B1 (en) | 2000-04-27 | 2003-03-04 | Georgetown University | Ligands for metabotropic glutamate receptors and inhibitors of NAALADase |
| JP5095050B2 (ja) | 1999-04-28 | 2012-12-12 | ジョージタウン ユニバーシティー | 代謝調節型グルタミン酸受容体のリガンド、及び、ＮＡＡＬＡＤａｓｅの阻害剤 |
| WO2001092274A2 (en) | 2000-05-30 | 2001-12-06 | Guilford Pharmaceuticals Inc. | Naaladase inhibitors for treating retinal disorders and glaucoma |
| AU2001265111A1 (en) * | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| US7148250B2 (en) * | 2001-12-28 | 2006-12-12 | Guilford Pharmaceuticals Inc. | Indoles as NAALADase inhibitors |
| US20030162694A1 (en) * | 2002-02-04 | 2003-08-28 | James Meyerhoff | Novel treatment for pathological aggression |
| DE602004021476D1 (de) * | 2003-03-03 | 2009-07-23 | Eisai Corp North America | THIOLACTONE ALS NAALADase INHIBITOREN |
| US20090082305A1 (en) * | 2005-03-30 | 2009-03-26 | Kyowa Hakko Kogyo Co., Ltd. | Method of improving storage stability of substance |
| ES2819303T3 (es) | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| ES2684322T3 (es) | 2006-11-08 | 2018-10-02 | Molecular Insight Pharmaceuticals, Inc. | Heterodímeros de ácido glutámico |
| WO2010065899A2 (en) | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
| BR112012000209B8 (pt) | 2009-06-15 | 2021-07-27 | Molecular Insight Pharm Inc | heterodímeros de ácido glutâmico e seus processos de preparação |
| EP2338892A1 (de) * | 2009-12-18 | 2011-06-29 | Bayer Schering Pharma Aktiengesellschaft | Prostataspezifische Membranantigen-Inhibitoren |
| WO2012082903A2 (en) * | 2010-12-14 | 2012-06-21 | The Johns Hopkins University | Treatment of cognitive impairment in a subject with a neurological autoimmune disease |
| US9120837B2 (en) | 2012-01-06 | 2015-09-01 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
| HUE035739T2 (en) | 2013-01-14 | 2018-05-28 | Molecular Insight Pharm Inc | Triazine-based radiopharmaceuticals and radiological imaging agents |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143908A (en) | 1986-11-05 | 1992-09-01 | Merck & Co., Inc. | Antibacterial agents and potentiators of carbapenem antibiotics |
| US4927966A (en) * | 1987-06-04 | 1990-05-22 | The Research Foundation Of State University Of New York | 2-mercaptomethylglutaric acid derivatives |
| JPH0474197A (ja) | 1990-07-12 | 1992-03-09 | Naoyoshi Suzuki | 新規な免疫調整生理活性ペプチド |
| US6011021A (en) | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US5795877A (en) | 1996-12-31 | 1998-08-18 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5804602A (en) | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
| US5824662A (en) | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6071965A (en) | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US5863536A (en) | 1996-12-31 | 1999-01-26 | Guilford Pharmaceuticals Inc. | Phosphoramidate derivatives |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5902817A (en) * | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US5672592A (en) | 1996-06-17 | 1997-09-30 | Guilford Pharmaceuticals Inc. | Certain phosphonomethyl-pentanedioic acid derivatives thereof |
| US5977090A (en) | 1996-09-27 | 1999-11-02 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors |
| WO1998013046A1 (en) * | 1996-09-27 | 1998-04-02 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| ID18382A (id) * | 1996-09-27 | 1998-04-02 | Guilford Pharm Inc | Komposisi sediaan farmasi dan metoda pengobatan gangguan kompulsif dengan menggunakan inhibitor naaladase |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
| US6121252A (en) * | 1998-03-30 | 2000-09-19 | Guilford Pharmaceuticals Inc. | Phosphinic acid derivatives |
| MXPA01000144A (es) * | 1998-07-06 | 2002-10-17 | Guilford Pharm Inc | Inhibidores de naaladasa utiles como composiciones y compuestos farmaceuticos. |
-
1999
- 1999-07-01 US US09/345,782 patent/US6228888B1/en not_active Expired - Fee Related
-
2000
- 2000-06-30 DE DE60008753T patent/DE60008753D1/de not_active Expired - Lifetime
- 2000-06-30 JP JP2001507468A patent/JP2003503451A/ja active Pending
- 2000-06-30 MX MXPA02000255A patent/MXPA02000255A/es active IP Right Grant
- 2000-06-30 WO PCT/US2000/018260 patent/WO2001001974A2/en not_active Ceased
- 2000-06-30 EP EP00943374A patent/EP1202717B1/de not_active Expired - Lifetime
- 2000-06-30 AT AT00943374T patent/ATE260653T1/de not_active IP Right Cessation
- 2000-06-30 AU AU57851/00A patent/AU5785100A/en not_active Abandoned
- 2000-06-30 CA CA002378467A patent/CA2378467A1/en not_active Abandoned
- 2000-12-21 US US09/741,169 patent/US6376478B1/en not_active Expired - Fee Related
-
2002
- 2002-02-20 US US10/077,877 patent/US20030013687A1/en not_active Abandoned
-
2005
- 2005-11-23 AU AU2005237108A patent/AU2005237108A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US6376478B1 (en) | 2002-04-23 |
| US20030013687A1 (en) | 2003-01-16 |
| US6228888B1 (en) | 2001-05-08 |
| WO2001001974A3 (en) | 2002-03-07 |
| DE60008753D1 (de) | 2004-04-08 |
| WO2001001974A2 (en) | 2001-01-11 |
| AU5785100A (en) | 2001-01-22 |
| EP1202717B1 (de) | 2004-03-03 |
| MXPA02000255A (es) | 2002-06-21 |
| AU2005237108A1 (en) | 2005-12-15 |
| JP2003503451A (ja) | 2003-01-28 |
| CA2378467A1 (en) | 2001-01-11 |
| EP1202717A2 (de) | 2002-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
| ATE362363T1 (de) | Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden | |
| ATE279181T1 (de) | Verwendung von 5ht-6 antagonisten zur behandlung adhd | |
| DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
| DE60112766D1 (de) | Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen | |
| ATE554169T1 (de) | Smad7-inhibitoren zur behandlung von krankheiten des zns | |
| NO20000521L (no) | 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 põ fenylringen | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| ATE367380T1 (de) | Zur behandlung von zns-erkrankungen geeignete piperazinylchinolinderivate | |
| ATE271861T1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
| DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
| DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
| ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| TR200200278T2 (tr) | Kalsilitik bileşimler | |
| DE60027127D1 (de) | Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen | |
| DE60326742D1 (de) | Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| DE60130691D1 (de) | Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems | |
| DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen | |
| DE60026581D1 (de) | Indolderivate zur behandlung von depression und angstzuständen | |
| DE60020833D1 (de) | Melatonin zur behandlung von paralysen ausgelöst durch hirnschlag | |
| JO2724B1 (en) | 3-Alternative-5 -6-Amino Alkyl Indole-2-Carboxyl Acid Amide and Related Isotopes as Casein Kinase Inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |